8-K
filed November 25, 2025, 6:59 PM ET
ticker KALA
CIK 0001479419
other material
confidence high
sentiment neutral
materiality 0.85
KALA BIO enters $6M private placement, resolves Oxford default, appoints David Lazar as CEO
KALA BIO, Inc.
- First closing raised $1.8M from 900k Series AA preferred shares at $2/share; second closing up to $4.2M subject to stockholder approval.
- Oxford loan settlement: $2M cash and 1.62M common shares reduce loan by $7M; $1M initial cash due by Jan 15, 2026 or stockholder meeting.
- David Lazar appointed CEO and board chair; Mary Reumuth terminated as CFO; Gregory Perry resigns from board.
- Company terminated all remaining employees in October after Oxford foreclosure; now resumes operations with limited cash from placement.
- Stockholder meeting required before March 31, 2026 to approve share increase and conversion of preferred shares.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
KALA BIO, Inc. issued 900,000 Series AA Preferred Shares of preferred stock to the Investor for $2.00 per Series AA Preferred Share.
- Security
- preferred stock
- Shares
- 900,000 Series AA Preferred Shares
- Purchaser
- the Investor
- Consideration
- $2.00 per Series AA Preferred Share
Exact text from the filing
Company has agreed to issue and sell to the Investor at a first closing of the Private Placement to be held immediately following the execution of the Securities Purchase Agreement (the “First Closing”), 900,000 Series AA Preferred Shares, at a price per Series AA Preferred Share equal to $2.00, for aggregate gross proceeds of $1.8 million. The First Closing occurred on November 24, 2025
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
KALA BIO, Inc. issued 2,100,000 Series AAA Preferred Shares of preferred stock to the Investor for $2.00 per Series AAA Preferred Share.
- Security
- preferred stock
- Shares
- 2,100,000 Series AAA Preferred Shares
- Purchaser
- the Investor
- Consideration
- $2.00 per Series AAA Preferred Share
Exact text from the filing
Company has also agreed to issue and sell to the Investor at a second closing of the Private Placement (the “Second Closing”), 2,100,000 Series AAA Preferred Shares, at a price per Series AAA Preferred Share equal to $2.00, for aggregate gross proceeds of $4.2 million
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
KALA BIO, Inc.: Filed Certificate of Designations for Series AA Convertible Non-Redeemable Preferred Stock establishing rights, preferences, and privileges (effective 2025-11-24).
- Change
- charter amendment
- Effective
- 2025-11-24
Exact text from the filing
On November 24, 2025 (the “Filing Date”), the Company filed a Certificate of Designations, Preferences and Rights of Series AA Convertible Non-Redeemable Preferred Stock (the “Series AA Certificate of Designations”) with the Secretary of State of the State of Delaware with respect to the Series AA Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
KALA BIO, Inc. entered into Securities Purchase Agreement with the Investor valued at up to $6.0 million (effective 2025-11-23).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Investor
- Value
- up to $6.0 million
- Effective
- 2025-11-23
Exact text from the filing
On November 23, 2025 (the “SPA Effective Date”), the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the Investor, pursuant to which the Company agreed to issue and sell, in a private placement, shares
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.